Key takeaways
- A peptide marketed for use in people without FDA approval is an unapproved new drug, and FDA judges intended use from the whole sale, not the label alone.
- To qualify for the 503A exemptions, a licensed pharmacy compounds from bulk ingredients that meet a monograph, belong to an approved drug, or are on the 503A bulks list; none of the six 2026 peptides is on that list.
- Since 28 October 2026, HHS says it will not act against licensed pharmacies, federal facilities and physicians compounding six peptides on prescription under ten conditions; it is interim, non-binding and not an approval.
- FDA’s 2026 warning letters said “research use only” labels did not outweigh website evidence of human use.
- The common research peptides are not federally scheduled drugs; human growth hormone has its own criminal provision, 21 U.S.C. 333(e).
01How does US law classify a peptide?
Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), a peptide’s legal status depends less on its chemistry than on what it is for.
A product is a drug if it is intended for use in the diagnosis, treatment, mitigation or prevention of disease, or to affect the structure or any function of the body (FD&C Act section 201(g)(1)). It is a new drug if it is not generally recognised as safe and effective for the uses in its labelling (section 201(p)). A new drug may not be introduced into interstate commerce without an approved FDA application (section 505(a)).
A few peptides are FDA-approved prescription medicines; the compounds usually sold as “research peptides” are not. HHS’s October 2026 policy describes BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 as substances that are not components of any FDA-approved drug product.
Intended use is judged on evidence, not on the label alone. FDA’s regulation (21 CFR 201.128) defines intended use as “the objective intent of the persons legally responsible for the labeling”. It may be shown by “labeling claims, advertising matter, or oral or written statements” and by “the circumstances surrounding the distribution of the article”. Our page on what “research use only” means goes deeper.
02How are compounded peptides regulated? 503A, 503B and the bulks list
Compounding is a defined exception to the approval requirement. Section 503A covers state-licensed pharmacies, federal facilities and licensed physicians making a drug for an individual patient on a valid patient-specific prescription. Section 503B covers outsourcing facilities registered with FDA.
For a compounded drug to qualify for the 503A exemptions, each bulk ingredient must take one of three routes: it (1) meets an applicable USP or NF monograph, (2) is a component of an FDA-approved drug, or (3) appears on the 503A bulks list, which is created by regulation after FDA consults its Pharmacy Compounding Advisory Committee. The ingredient must also come from an FDA-registered establishment with a valid certificate of analysis. None of the six peptides in the 2026 HHS policy is on that list.
While the list is built, FDA sorts nominated substances into interim categories. BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 were in Category 2, the safety-concern category, from September 2023 until 22 April 2026. HHS records that, for each, “neither the placement nor the removal changed” its status under section 503A. Mechanics: our FDA categories explainer.
03What changed in 2026? An advisory vote, then an HHS policy
On 23–24 July 2026 FDA’s Pharmacy Compounding Advisory Committee voted in favour of adding six peptides to the 503A bulks list: BPC-157, KPV, TB-500, MOTS-c, epitalon and Semax. FDA’s drug centre (CDER) had recommended against listing each of them. The vote is advice, not a rule. Details and the reported counts: the 2026 PCAC vote.
On 28 October 2026 HHS filed an “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances”. It was published in the Federal Register on 30 October (91 FR 68526, Docket HHS-OASH-2026-0496). Until each peptide is addressed in a final rule, HHS “does not intend to take action against a State-licensed pharmacy, Federal facility, or licensed physician” compounding one of the six, when all ten conditions are met. In summary:
- The ingredient is one of the six listed in Appendix A, with the identity and route limits set in Appendix B.
- It comes from an FDA-registered, CGMP-compliant original manufacturer, with a certificate of analysis covering identity, purity, potency and contaminants such as endotoxin.
- Serious adverse events and product quality problems are reported to FDA’s MedWatch programme and to the states involved.
- The label says: “This is a compounded drug product. Not for resale.”
- One active ingredient per product, with limits on dosage forms and on any device packaged with it.
- Every other FD&C Act requirement still applies, including a patient-specific prescription.
What it does not cover. The policy “does not establish any rights for any person and is not binding on HHS or the public”, and HHS “may revisit” it if “a safety signal or product quality issue arises”. It is not an approval and adds nothing to the bulks list. Its scope is compounding by licensed pharmacies, federal facilities and physicians from registered, documented ingredients. Products sold as research chemicals or as supplements fall outside it. HHS states the policy is meant to “discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients.” The Federal Register notice calls it a “draft” policy and invited comments for two weeks after publication; that window has closed. More: the HHS policy explained.
04What did FDA tell online peptide sellers?
FDA sent warning letters to online peptide sellers during 2026. Each letter we read followed a review of the seller’s website and concluded that the products were unapproved new drugs. One dated 24 August 2026, posted on fda.gov on 1 September, shows the pattern.
On labels: “Despite statements on your product labeling marketing your products for ‘research use only’ and ‘not for human consumption,’ evidence obtained from your website establishes that your products are intended to be drugs for human use.” On solvents: the seller marketed bacteriostatic water “as a solvent for reconstituting your products, thus, providing the means to prepare an injectable drug for human administration.”
Two details matter. First, the website text FDA quoted as evidence of intended use was written in research language: product descriptions saying a compound was “studied for” an effect or “considered in preclinical models”. Second, the letter warns that failing to correct the violations “may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.”
05Are peptides controlled substances in the US? Federal schedules and state rules
Federal drug scheduling. The federal controlled-substance schedules are in 21 CFR Part 1308. None of the six peptides in the HHS policy appears there, and neither do ipamorelin, CJC-1295, melanotan II or sermorelin. For these peptides the live legal question is FDA drug law, not drug-scheduling law.
Human growth hormone is a separate case. It is not in the schedules either, but 21 U.S.C. 333(e) makes it a federal crime, punishable by up to 5 years in prison (10 if the offence involves a person under 18), to knowingly distribute it, or possess it with intent to distribute, “for any use in humans other than the treatment of a disease or other recognized medical condition” authorised by FDA and prescribed by a physician. The statute defines it as somatrem, somatropin or an analogue of either.
States add their own layer. State boards license the people who prescribe and compound, and in 2026 they moved in both directions. This table lists only statements we have read at the source; other states may have acted.
| State | Who | What it said | Date |
|---|---|---|---|
| Mississippi | Boards of Medical Licensure, Nursing and Pharmacy (joint) | “Under no circumstances is it permissible for a healthcare provider to compound, administer, or dispense a non-FDA approved or research-grade peptide to a patient.” Consent forms calling a product “research-grade” do not remove the provider’s liability. | 19 Aug 2026 |
| Louisiana | Legislature, Act 374 (SB253) | No licensing board may stop a licensed pharmacist compounding and dispensing peptides in compliance with 503A and applicable USP chapters. | In force 1 Aug 2026 |
06What don’t we know about US peptide rules?
Whether FDA will list any of the six. No proposed rule for the 503A bulks list has appeared in the Federal Register as of 17 November 2026.
How state boards will respond. The Mississippi statement predates the HHS policy; we have not seen a state board respond to it directly.
How long the HHS policy will last. It runs until each peptide is addressed in a final rule, unless HHS revisits it earlier.
07Changes to this page
17 Nov 2026. Page written and checked against every document in the sources list below.
Changes to this page are logged here and in the regulatory changelog.
This is a plain-English summary of public documents, checked on 17 Nov 2026. It is not legal advice.